SCHEMBL5645562

SCHEMBL5645562

C1CC(CNCC2CC2)CCN1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GNAI3 P08754 1/20 0.53
GNAO1 P09471 1/20 0.53
GNAI1 P63096 1/20 0.53
ANPEP P15144 1/20 0.50
ERAP2 Q6P179 1/20 0.50
ALOX15 P16050 2/20 0.47
TSHR P16473 1/20 0.47
PRMT5 O14744 1/20 0.46
WDR77 Q9BQA1 1/20 0.46
SLC6A1 P30531 2/20 0.43
GABRA5 P31644 2/20 0.43
GABRB2 P47870 2/20 0.43
SLC6A12 P48065 2/20 0.43
SLC6A11 P48066 2/20 0.43
SLC6A13 Q9NSD5 2/20 0.43
GABRA1 P14867 1/20 0.43
GABRR1 P24046 1/20 0.43
GABRA4 P48169 1/20 0.43
EPHX1 P07099 3/20 0.42
EPHX2 P34913 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21987001 0.97 GNAI3 (0.55) GNAI3GNAO1GNAI1ANPEPERAP2
SCHEMBL8042671 0.87 GNAI3 (0.48) GNAI3GNAO1GNAI1ANPEPERAP2
SCHEMBL12531248 0.84 GNAI3 (0.46) GNAI3GNAO1GNAI1ANPEPERAP2
SCHEMBL5963013 0.82 GNAI3 (0.75) GNAI3GNAO1GNAI1ANPEPERAP2
SCHEMBL19992760 0.82 GNAI3 (0.48) GNAI3GNAO1GNAI1ANPEPERAP2
SCHEMBL4711032 0.82 GNAI3 (0.58) GNAI3GNAO1GNAI1ANPEPERAP2
SCHEMBL4712878 0.82 ANPEP (0.54) GNAI3GNAO1GNAI1ANPEPERAP2
SCHEMBL1007436 0.82
SCHEMBL669897 0.80 GNAI3 (0.56) GNAI3GNAO1GNAI1ANPEPERAP2
SCHEMBL16083804 0.80 GNAO1 (0.47) GNAI3GNAO1GNAI1ANPEPERAP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7279470-B2 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase NOVO NORDISK A/S (DK) 2007-10-09 US disclosed
US-7067517-B2 Use of compounds for decreasing activity of hormone-sensitive lipase NERO NORDISK A/S (DK) 2006-06-27 US disclosed
EP-1458374-A2 COMPOUNDS AND USES THEREOF FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-09-22 EP disclosed
EP-1458375-A2 COMPOSITIONS FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-09-22 EP disclosed
US-20030166644-A1 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase NOVO NORDISK A/S (DK) 2003-09-04 US disclosed
US-20030166690-A1 Use of compounds for decreasing activity of hormone-sensitive NOVO NORDISK A/S (DK) 2003-09-04 US disclosed
WO-2003051842-A2 COMPOSITIONS DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2003-06-26 WO disclosed
WO-2003051841-A2 COMPOUNDS AND USES THEREOF FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2003-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030166644-A1 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase LIPE, PNLIP, LPL GNAI3 1673/4885GNAO1 2414/4885GNAI1 1744/4885
US-20030166690-A1 Use of compounds for decreasing activity of hormone-sensitive LIPE, PNLIP, LPL GNAI3 1869/4885GNAO1 2297/4885GNAI1 1976/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.